Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NEO-PTC-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Neon’s initial Phase 1 clinical trial of NEO-PTC-01 will be conducted in patients with metastatic melanoma who are not responsive to checkpoint inhibitors.
Product Name : NEO-PTC-01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : NEO-PTC-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NEO-STC-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : BioNTech
Deal Size : $67.0 million
Deal Type : Acquisition
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
Details : This acquisition to expand BioNTech's capabilities and strengthens its immunotherapy pipeline.
Product Name : NEO-STC-01
Product Type : Cell and Gene therapy
Upfront Cash : $67.0 million
January 16, 2020
Lead Product(s) : NEO-STC-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : BioNTech
Deal Size : $67.0 million
Deal Type : Acquisition